Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Myeloid Leukemia AML - Novel Therapy, excluding Transplantation II

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML

Watch Session

111 Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Hartmut Döhner, Andrew H Wei, Pau Montesinos, et al.

 

112 SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, Carlos Enrique Vigil, et al.

 

113 Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, Xinyue Wang, Max Harris, et al.

 

114 Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, Stephane De Botton, Thomas Cluzeau, et al.

 

115 Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, Jessica K. Altman, Kristen M. Pettit, et al.

 

116 Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

Inge Van Der Werf, Phoebe Mondala, Raymond Diep, et al.